Study Suggests Validity of Personal Genetic-Risk Data May Be Inflated | GenomeWeb

By analyzing the power of two widely used statistical methods to evaluate the association between certain genetic abnormalities and diseases, researchers have concluded that consumer genomics companies may have rushed to market with their service offerings, and may be inflating the value of personalized medicine.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.